VivoSeq
Gastroenterology

Crohn Disease

13

Pipeline Programs↗

18

Active Trials↗

6

Companies Involved↗

Crohn Disease is an emerging landscape with 13 programs across 6 companies. The most active players are Eli Lilly, Salix, AbbVie. 1 therapy is approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

30/100

Mech. Concentration

25/100

Completion Rate

50/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

4 programs

Phase 2S

Salix

1 program

Phase 2AbbVie logo

AbbVie

1 program

Phase 3Johnson & Johnson logo

Johnson & Johnson

4 programs

ApprovedM

Medeor Therapeutics, Inc.

1 program

PreclinicalL

LOGEX

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

9programs
Small molecule556%
Monoclonal antibody444%

Modality classified for 75% of 16 pipeline programs.

Analysis

Trial Status

27

clinical trials

Recruiting13 · 48%
Completed4 · 15%
Not yet recruiting4 · 15%
Terminated3 · 11%
Unknown status1 · 4%
Withdrawn1 · 4%
Other1 · 4%

Clinical Trials

Trial Activity

27 trials

MSC Intratissular Injection in Crohn Disease Patients
Recruiting·UUniversity of Liege·Phase 1/2·NCT03901235·60 enrolled
Repeated and Multiple Fecal Microbiota Transplantations Plus Partial Enteral Nutrition as the First-line Treatment in Active Pediatric Crohn's Disease
Recruiting·TTongji Hospital·Preclinical·NCT05321758·50 enrolled
Repeated and Periodic Fecal Microbiota Transplantation in Children With Active and Refractory Crohn's Disease
Recruiting·—·Preclinical·NCT05321745·40 enrolled
Surgery Versus Biologics for Symptomatic Stricturing Crohn's Disease : an Open-label, Single-center, Randomized Controlled Trial
Recruiting·—·Preclinical·NCT05421455·138 enrolled
RRA-18896: An Observational Study to Assess the Long-term Safety of Ustekinumab Versus Other Biologic Therapies Among Patients With Crohn's Disease: A New-User Cohort Study Using the Department of Defense Electronic Health Records Database
Recruiting·Johnson & Johnson logoJohnson & Johnson·N/A·NCT04372108·1,056 enrolled
A Phase 2, Multicenter, Randomized, Open-Label, Active-Controlled Study to Investigate LY4395089/Mirikizumab Co-administration Compared With Mirikizumab in Adults With Moderately to Severely Active Crohn's Disease
Recruiting·Eli Lilly logoEli Lilly·Phase 2·NCT07483099·60 enrolled
Efficacy of Guselkumab in Chinese Participants With Crohn's Disease Following Loss of Response to Ustekinumab
Recruiting·Johnson & Johnson logoJohnson & Johnson·Approved·NCT07310095·78 enrolled
A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Recruiting·Johnson & Johnson logoJohnson & Johnson·Preclinical·NCT07196722·1,092 enrolled
A Phase 3, Randomized, Double-blind, and Active-controlled Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT07577843·460 enrolled
A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab Versus Risankizumab in the Treatment of Participants With Moderately to Severely Active Crohn's Disease
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT07499232·530 enrolled
Pilot Study on the Treatment of Anal Fistulas in Crohn's Disease Patients Using Alofisel Versus Fat Autologous Stem Cells
Recruiting·NNantes University Hospital·N/A·NCT05974280·20 enrolled
Gastro-intestinal Biopotential Recorder by Means of Surface ELEctrodes
Recruiting·CCentral Hospital, Nancy, France·Preclinical·NCT06197334·60 enrolled
Standardized Microbiota Transplant Therapy in Crohn's Disease
Recruiting·UUniversity of Minnesota·Phase 2·NCT06631586·120 enrolled
A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study of Ustekinumab in Pediatric Clinical Study Participants (2 to <18 Years of Age)
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT05092269·159 enrolled
Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease
Not yet recruiting·SStanford University·Phase 1/2·NCT06986382·14 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)